BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (November 2015)

25 slides from BioSpecifics Technologies's investor presentation, Nov 18, 2015

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE tin. 5 BioSpecifics November 2015

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Company Overview

    Company Overview BioSpecifics (Nasdaq: BSTC) is a profitable biopharma company. Originator of collagenase based-therapies. Receives revenues from XIAFLEX® milestones, royalties on net sales, mark-up on COGS and sublicense income by partner Endo. Future revenue growth opportunities emerging from inte

  4. Slide 4: Unlocking Vast Potential of XIAFLEX

    Unlocking Vast Potential of XIAFLEX® First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options » BioSpecifics has positive clinical results in 12 indications: Dupuytren’s contracture’ Adhesive capsulitist Scarred te

  5. Slide 5: Dupuytren's Contracture

    XIAFLEX® for Dupuytren’s Contracture First, Effective Non-Surgical Treatment Option Collagen cord in hand causing one or more fingers to contract toward Definition & Key the palm Complications Limits range of motion and impairs quality of life Affects up to 7% of adults in the U.S. Pre- treatment: P

  6. Slide 6: Commercial Highlights for DC

    Commercial Highlights for DC ~6,400 vials shipped 3Q15 in U.S. 14% year-over-year increase ~1.2 vials/patient First commercial sale in Japan in September 2015 Updated U.S. label including recurrence and retreatment data approved in May 2015 E.U. label expansion approved in November 2015, following O

  7. Slide 7: Peyronie's Disease

    XIAFLEX® for Peyronie’s Disease First, Effective Non-Surgical Treatment Option Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases res Associated with increased pain, painful erections, palpable Definition & plaque, penile deformity and erectile d

  8. Slide 8: Commercial Highlights for PD

    Commercial Highlights for PD ~7,500 vials shipped 3Q15 in U.S. 33% year-over-year growth ~4.5 vials/patient Continued commercial progress and growth with certified physicians and new patients As of 3Q15 there were 2,325 certified physicians and 11,600 cumulative patients treated Approval in Switzerl

  9. Slide 9: Pipeline Programs

    XIAFLEX® Pipeline Programs Future Revenue-Generating Opportunities Adhesive Capsulitis Phase 2b to initiate [Phase 2b to initiate shortly Cellulite Phase 2b to initiate shortly ee Phase 2 top-line results 1H16 fone Endo has license for further development Hires Lateral Thigh Endo recent early opt-in

  10. Slide 10: Adhesive Capsulitis

    XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Definition & Complications == z V = ce Common available treatment options are often painful and can require anesthesia Only FDA Approved Long-term intensive physical therapy, corticosteroids, manipulation Nonsurgi

  11. Slide 11: Phase 2b Study of XIAFLEX in Adhesive Capsulitis/FSS

    Phase 2b Study of XIAFLEX® in Adhesive Capsulitis/FSS Objective & Rationale 321 Patients Enrolled at 35 Sites in the U.S. and Australia Outcome Measures Source: Endo Intemational, ple Double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopathi

  12. Slide 12: Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis/FSS

    Phase 2b Study Results of XIAFLEX® in Adhesive Capsulitis/FSS Strong, similar drug effect for key measures including forward flexion, shoulder abduction, external and internal rotation across both Phase 2a and Phase 2b trials Similar patient improvement in pain seen across both trials Increased and

  13. Slide 13: Cellulite

    XIAFLEX® for Cellulite Definition Significant Market Opportunity as First Nonsurgical Therapy Positive Top-line Results Reported from Phase 2a Study ‘Source: Endo International, ple Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affec

  14. Slide 14: Cellulite: Positive Top-line Data from Phase 2a Study

    XIAFLEX® for Cellulite Positive Top-line Data from Phase 2a Study Top-line Data from Phase 2a Study Mid and high level XIAFLEX® doses demonstrated statistically significant improvement in cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” wi

  15. Slide 15: Human Lipomas

    XIAFLEX® for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Definition Potential to be Only Approved Nonsurgical Therapy U.S. Market Opportunity Top-Line Data from Phase 2 Opt-In Study Expected in 1H16 Encapsulated deposits of benign fatty tumors; detected as bulges under the skin No FDA

  16. Slide 16: Positive Phase Clinical Trial Results

    Positive Phase 2 Clinical Trial Results Open label, dose escalation Phase 2 trial: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of commercial dose) achieved best

  17. Slide 17: Lipomas in Canines

    XIAFLEX® for Lipomas in Canines Key Complications Potential to be Only Approved Nonsurgical Therapy Chien-804 Trial Results Lipomas can seriously restrict motion in older dogs Surgery can be risky due to the use of general anesthesia - especially for older dogs 1.7M dogs affected in the U.S. annuall

  18. Slide 18: Uterine Fibroids

    XIAFLEX® for Uterine Fibroids Endo Encouraged by Results Reported to Date Definition & Key Complications Potential to be Nonsurgical Therapy Option U.S. Market Opportunity Encouraging Preclinical Data ‘Sours of data: Cardozo ER, Clark AD, Banks NK, Henne MB, Stepmann BJ, Segars JH. The estimated ann

  19. Slide 19: Lateral Thigh Fat

    XIAFLEX® for Lateral Thigh Fat Recent Early Opt-In by Partner Endo Definition & Complications Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict t

  20. Slide 20: Plantar Fibromatosis

    XIAFLEX® for Plantar Fibromatosis Recent Early Opt-In by Partner Endo Definition & Complications Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Peyronie’s disease and a

  21. Slide 21: Endo Partnership for Development and Commercialization of XIAFLEX

    Endo Partnership for Development and Commercialization of XIAFLEX® >$67.9M Received to Date Future Payments Due to BioSpecifics from Endo Endo Opt-In Rights Sublicense Income from Endo Partnerships $67.9M received in licensing, sublicensing, milestone, COGS, and royalty payments as of September 30,

  22. Slide 22: Corporate Highlights

    Corporate Highlights » Vast opportunity for growth in revenues from XIAFLEX® sales and approval in new indications = Strong IP portfolio Long-term patent protection for XIAFLEX® : Dupuytren’s Contracture: XIAFLEX® has Drug product composition patent until 2028 and Biologic Exclusivity until 2022 Pey

  23. Slide 23: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the nine months ended 09/30/15 09/30/14 Cash and equivalents, and investments $32,824,471 $21,961,252 Income Statement Revenues $16,611,268 Other income 65,056 Costs and expenses (6,062,469) Provision for income taxes (3,654,772)

  24. Slide 24: Anticipated Upcoming Pipeline Milestones

    Anticipated Upcoming Pipeline Milestones eae O Phase 2 placebo-controlled opt-in trial top-line results in 1H16 oe QO Refining development plan Adhesive O Initiate Phase 2b trial shortl Capsulitis y Cellulite Q Initiate Phase 2b trial shortly Canine Coenen O Endo has license to develop Fat & Plantar

  25. Slide 25: Innovators in the development & commercialization of injectable collagenase

    a Innovators in the development & commercialization of INJECTABLE COLLAGENASE — a . BioSpecif CS November 2015

BioSpecifics Technologies — Investor Presentation (November 2015) on 6ix